Indications for further investigation of targeted agents based on the outcomes of this review
| Indication for further investigation | Targeted agent |
| Further investigation warranted | Bevacizumab Cediranib Trastuzumab AZD1775 |
| Further investigation may be warranted | Pazopanib Sunitinib |
| No evidence to support further investigation | Abagovomab Nintedanib Lonafarnib Erlotinib Dasatinib |